stock.name

CSL Ltd. - ADR

CSLLY

Market Cap$88.42B
Close$

Compare CSL Ltd. - ADR

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
CSL Ltd. - ADRCSL Ltd. - ADR00%---
marketMarket Avg59.61.27%31%6.41
HealthcareHealthcare Avg62.31.27%15%7.30.9

Earnings Call Q4 2023

August 15, 2023 - AI Summary

CSL delivered strong full-year results, with revenue up 31% at constant currency and NPATA of $2.6 billion, up 20%.
The CSL Behring business saw strong growth in its Ig franchise, with sales up 21%. Plasma collections reached record levels, and the company dosed its first patients with HEMGENIX, a gene therapy for hemophilia B.
CSL Seqirus achieved strong sales growth, driven by FLUCELVAX, which was up 30%. The company also signed a licensing agreement with Arcturus Therapeutics for next-generation mRNA vaccine technology.

Exclusive for Stockcircle Pro members

Sign upSign Up

Share Statistics

Market cap$88.42 Billion
Enterprise Value-
Dividend Yield$1.24 (0.0%)
Earnings per Share$0.0
Beta0.0
Outstanding Shares966,505,458
Avg 30 Day Volume27,748

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio0.0
PEG-
Price to Sales-
Price to Book Ratio-
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income-
Total Debt to Enterprise-
Debt to Equity-

Revenue Sources

No data

ESG Score

No data

About CSL Ltd.

CEO: Paul Perreault